Question follow-through · 29295
Rare Diseases: Medical Treatments
To ask the Secretary of State for Health and Social Care, what assessment she has made of whether the National Institute for Health and Care Excellence's cost-effectiveness methodology adequately reflects the particular circumstances of medicines for rare
About this written question
A written question asks a government minister for information in writing. Parliament publishes the question and any answer.
- Answering body
- Department of Health and Social Care
- Tabled
- 11 Sept 2026
- Target answer date
- 15 Sept 2026
- Answer
- 22 Sept 2026 · 11 calendar days after tabling
Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.
Votes on this topic
- Terminally Ill Adults (End of Life) Bill: Second Reading · 11 Sept 2026
- Health Bill: Report Stage: Amendment 1 · 8 Sept 2026
- Health Bill: Report Stage: New Clause 143 · 8 Sept 2026
These Commons divisions share a topic label. The question did not necessarily lead to a vote.
Recorded timeline
11 Sept 2026
Question tabled
To ask the Secretary of State for Health and Social Care, what assessment she has made of whether the National Institute for Health and Care Excellence's cost-effectiveness methodology adequately reflects the particular circumstances of medicines for rare
15 Sept 2026
Target answer date
Date supplied by the official written-questions record.
22 Sept 2026
Answer published
The National Institute for Health and Care Excellence (NICE) has been able to recommend many medicines licensed for the treatment of rare diseases for use on the National Health Service where companies engage constructively in the process and price their ...
Official data retrieved 1 Oct 2026.
Later records
Possible follow-up questions
Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.
No later same-department questions indexed.
This is an absence in covered public data, not evidence that no follow-up occurred elsewhere.